Diet therapy in gestational diabetes mellitus (GDM) has focused on carbohydrate restriction but is poorly substantiated. In this pilot randomized clinical trial, we challenged the conventional low-carbohydrate/higher-fat (LC/CONV) diet, hypothesizing that a higher-complex carbohydrate/lower-fat (CHOICE) diet would improve maternal insulin resistance (IR), adipose tissue (AT) lipolysis, and infant adiposity.
However, this approach often necessitates an increase in dietary fat given that protein intake is relatively constant (3) . Higher dietary fat in humans and animals has been shown to promote insulin resistance (IR) (3) . There is concern that increasing maternal IR could shunt more nutrients to the fetus and increase fetal fat accretion (3) . Animal and nonhuman primate models support an intrauterine influence of dietary fat in promoting offspring adiposity, hepatic steatosis, and metabolic syndrome (4) . In humans, maternal triglycerides (TGs) and free fatty acids (FFAs) are also strong predictors of excess fetal fat accretion (5, 6) . Thus, a low-carbohydrate, higher-fat (LC/CONV) diet in obese women with GDM with preexisting IR may have unintended consequences on infant health.
We set out to elucidate the effects of prepared diets on glucose and lipid profiles, adipose tissue (AT) IR, and infant adiposity in GDM. This highly controlled pilot began with a short-term crossover design. Women were randomized to either a conventional LC/CONV diet or a higher-complex carbohydrate, lower-fat (CHOICE, choosing healthy options in carbohydrate energy) diet at the time of GDM diagnosis. They remained on the second diet through delivery. We have previously published that in the randomized crossover trial, both diets resulted in controlled glycemia (7) . We hypothesized in this pilot study that maternal IR (HOMA-IR, AT) and offspring adiposity would be improved after continuing the CHOICE diet versus LC/CONV for 6-7 weeks until delivery.
RESEARCH DESIGN AND METHODS

Subjects
This study was approved by the Colorado Multiple and the Kaiser Permanente Colorado institutional review boards. As previously described (7), GDM was diagnosed at 24-28 weeks using Carpenter and Coustan criteria (1) . Women were aged 20-36 years and had BMI 26-39 kg/m 2 , had fasting blood glucose (FBG) ,110 mg/dL without comorbidities, and were treated with diet alone.
Study Protocol
Twelve women started diet intervention (all meals provided) in gestational weeks 30-31 and continued until delivery (7) . A fasting (10-h) blood sample was collected at baseline (31 weeks), blood and AT were collected after 6-7 weeks of diet (37 weeks), and newborns were studied 2 weeks after birth. Women self-monitored fasting and 2-h postprandial glucose (targets ,95 and ,120 mg/dL, respectively) throughout pregnancy.
Techniques
Diet Protocol
Thorough information describing the diet protocol has been previously published (7). Diets were eucaloric and macronutrient distributions were as follows: LC/CONV, 40% carbohydrate/45% fat/15% protein; CHOICE, 60% carbohydrate/25% fat/15% protein, as previously described (7) . Both diets were matched for fat (35% saturated fatty acids/45% monounsaturated fatty acids/20% polyunsaturated fatty acids) and simple sugars (#18% of kilocalories), and daily kilocalories were partitioned as breakfast 25%/lunch 25%/ dinner 30%/snacks 20%. Both diets contained mainly low-to moderate-glycemic index foods. As previously described (7), we define "complex carbohydrate" as "polysaccharides and starches primarily derived from grains, vegetables, and fruits that tend to attenuate a sharp postprandial rise in plasma glucose." Fiber content was similar (LC/CONV ;23.5 g/day; CHOICE ;29.3 g/day). Menus were tailored to food preferences, and all meals were prepared by the Clinical Translational Research Center (CTRC) Nutrition Services. Women met with investigators when they picked up their meals (every 72 h).
AT Biopsy
Subcutaneous AT (10-h fasted) was biopsied (n 5 11; one subject declined) from the upper gluteal/flank region using our established protocol (8, 9) . Isoproterenolstimulated AT lipolysis 6 insulin was measured as described by Engfeldt et al. (10) . Gene expression (mRNA) for markers of inflammation and lipogenesis associated with IR in AT was measured by quantitative RT-PCR (11). In brief, RNA was isolated from AT samples using RNeasy (Qiagen, Valencia, CA), reverse transcribed (Bio-Rad, Hercules, CA), and run on an iQ5 instrument (Bio-Rad). mRNA was normalized to the mean of reference genes RPL13a, UBC, and TFRC.
Blood Measures
Lipids, ApoB, ApoA1, and Lp(a) were measured using VAP cholesterol testing (Atherotech, Birmingham, AL) and OxLDL by ELISA (Mercodia, Uppsala, Sweden) as previously reported (7).
Infant Body Composition
Infant weight, length, and adiposity (% fat by PEAPOD; Cosmed Inc., Concord, CA) were measured by the same investigators 2 weeks after birth.
Sample Size Determination and Statistical Methods
This pilot and feasibility study was an extension of the published randomized crossover study (7) performed to estimate power for a larger randomized clinical trial. Reported outcomes were prespecified, but not powered, end points. Equality of variance was confirmed using the Levene test. Paired Student t tests assessed within-group changes; independent Student t tests assessed between-group differences and change from baseline. Correlation analyses were Pearson R (SPSS V22.0; IBM, Armonk, NY).
RESULTS
Subject Characteristics
Subject characteristics did not differ statistically between maternal groups (Table 1) . However, in the CHOICE group, four women were Caucasian and two were Asian. In LC/CONV, two were Caucasian, three were Hispanic, and one was Asian. Physical activity was not different between groups (7). Women attended all clinic visits and picked up all prepared meals for the duration of the protocol.
Blood Lipid, Glucose, and Insulin
There were no effects of either diet on cholesterol or lipoproteins (Table 1) . Fasting TGs increased within both groups (P , 0.01, LC/CONV; P , 0.05, CHOICE). Both FBG (P , 0.05) and FFAs (P 5 0.06) decreased on the CHOICE diet, whereas FBG increased on LC/CONV (P , 0.05) ( Table 1) .
AT Lipolysis and Markers of Inflammation
Insulin suppression of isoproterenolstimulated lipolysis was higher on CHOICE versus LC/CONV (56 vs. 31%, respectively, P , 0.01) ( Table 1) . AT gene expression of proinflammatory biomarkers interleukin1b (IL-1b), tumor necrosis factor-a (TNF-a), toll-like receptor-4 (TLR-4), cluster of differentiation molecule 11B (CD11B), CD11C, CD1D, and glycoprotein receptor 43 (GPR43) was lower in AT from CHOICE versus LC/CONV subjects (all P , 0.01) ( Table 1) . Maternal fasting insulin (r 5 0.697, P 5 0.01) and HOMA-IR (r 5 0.731, P , 0.01) at 37 weeks' gestation were correlated with infant adiposity.
CONCLUSIONS
This highly controlled pilot intervention demonstrated that women with GDM randomized to CHOICE compared with LC/CONV diet have greater AT insulin sensitivity (i.e., better suppression of isoproterenol-stimulated lipolysis) and strikingly lower proinflammatory gene expression. FBG was also reduced after CHOICE compared with an increase after LC/CONV, both of which limited simple carbohydrates. Fasting FFAs decreased on both eucaloric diets, but with a greater decrement on the CHOICE diet (33% compared with 19%). Among all women with GDM, fasting insulin and HOMA-IR measured at 37 weeks' gestation were strong correlates of increased infant adiposity. Taken together, our data suggest that the CHOICE diet, which is characterized by including more nutritious complex carbohydrates, may improve AT IR, resulting in a lower FBG and FFA exposure to the fetus. Therefore, AT insulin action may be an important target for diet therapy in GDM.
We previously demonstrated that glycemia was well controlled in these women with GDM when they consumed both diets for 3 days each in a randomized crossover trial. Importantly, postprandial FFAs were lower on CHOICE compared with the LC/CONV diet (7). Fasting glycemia was the strongest predictor for large-for-gestational-age infants in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) trial (12) , and in this pilot, prolonged exposure to the CHOICE diet decreased FBG. Mounting evidence supports that maternal TGs and FFAs also contribute to excess fetal fat accretion (5, 6) . In the second and third trimester, systemic IR increases to ensure adequate nutrient flux to the fetus, but insulin clamp studies demonstrate that women with GDM already enter pregnancy with chronic IR (13) and/or insufficient b-cell reserve. We have shown worsened skeletal muscle IR in GDM (14) , and these data are the first to support an effect of diet on AT IR. Lowering dietary fat may improve insulin signaling through suppressing inflammation, resulting in less circulating FFAs, which we observed in subjects on the CHOICE diet (3). The reduced pattern of AT inflammatory and cytokine gene expression with CHOICE further supports this assertion. A reduction in the short-chain fatty acid receptor GPR43 suggests a potential favorable influence on the microbiota on the CHOICE diet (15) .
Limitations to our study include the following: 1) the small sample size, 2) lack of a baseline (31 weeks) AT biopsy, and 3) lack of a systemic measure of IR (beyond HOMA-IR estimates). It is a further limitation that three of six women in the LC/CONV group were Hispanic, as this could have influenced the outcomes. However, the well-matched women, highly controlled randomized design in which all meals were provided, and exclusion of the confounding effects of glucose-lowering medications make these data provocative (3) . Based on these pilot data, we are conducting a larger randomized clinical trial powered to detect a between-group difference in infant adiposity following these two diets.
Our pilot data raise questions about current low-carbohydrate dietary recommendations for women with GDM. If maternal IR is a key regulator of nutrient exposure to the fetal-placental unit, and it may be attenuated by reducing dietary fat, then potential long-term programming effects and excessive fetal growth could be modifiable by diet therapy in GDM.
